Data / Drug companies / Tolterodine tartrate
Tolterodine tartrate: 13 companies and 29 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Tolterodine tartrate is listed in the FDA National Drug Code Directory by 13 companies, with 29 products in commercial distribution. 28 of the products (96.6%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule, extended release; tablet, film coated; tablet, and the newest product started marketing on June 24, 2026.
The request: Get every company that lists tolterodine tartrate in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 13
- Products
- 29
- Generic (ANDA) products
- 28 (96.6%)
- Application numbers
- 12
- Routes
- Oral
- Brand names
- Detrol
- openFDA record search
- api.fda.gov
Companies that list tolterodine tartrate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Camber Pharmaceuticals, Inc. | 4 | capsule, extended release; tablet, film coated | Generic drugs (ANDA) | August 2, 2021 |
| Teva Pharmaceuticals USA, Inc. | 4 | capsule, extended release; tablet, film coated | Generic drugs (ANDA) | March 20, 2017 |
| Unichem Pharmaceuticals (USA), Inc. | 4 | capsule, extended release; tablet | Generic drugs (ANDA) | October 1, 2024 |
| Ajanta Pharma USA Inc. | 2 | capsule, extended release | Generic drugs (ANDA) | June 25, 2020 |
| Ani Pharmaceuticals, Inc. | 2 | capsule, extended release | Generic drugs (ANDA) | August 29, 2019 |
| Golden State Medical Supply, Inc. | 2 | capsule, extended release | Generic drugs (ANDA) | August 19, 2019 |
| Macleods Pharmaceuticals Limited | 2 | tablet, film coated | Generic drugs (ANDA) | October 8, 2020 |
| Major Pharmaceuticals | 2 | capsule, extended release | Generic drugs (ANDA) | June 24, 2026 |
| Rising Pharma Holdings, Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | January 24, 2020 |
| Slate Run Pharmaceuticals, LLC | 2 | capsule, extended release | Generic drugs (ANDA) | April 12, 2021 |
| A-S Medication Solutions | 1 | capsule, extended release | Generic drugs (ANDA) | March 20, 2017 |
| Proficient Rx LP | 1 | tablet, film coated | Generic drugs (ANDA) | November 1, 2015 |
| Viatris Specialty LLC | 1 | tablet, film coated | New drug applications (NDA) | August 1, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule, extended release | 17 | 58.6% |
| Tablet, film coated | 10 | 34.5% |
| Tablet | 2 | 6.9% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 28 | 96.6% |
| New drug applications (NDA) | 1 | 3.4% |
Pharmacologic classes
| Class | Products |
|---|---|
| Cholinergic Muscarinic Antagonist | 29 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.